Overview
Soft tissue tumors and sarcomas are malignant neoplasms arising from connective tissues, encompassing a diverse group of diseases with varying prognoses and treatment approaches 1.Diagnosis
Imaging studies (MRI, CT scans) are essential for initial assessment and staging 1.
Biopsy confirmation is required for definitive diagnosis 1.
Echocardiography and serum markers may be used to monitor cardiotoxicity in patients receiving anthracycline-based chemotherapy 1.Management
First-line treatment often includes surgery, with adjuvant chemotherapy for high-risk cases 1.
Anthracycline-based regimens (e.g., doxorubicin, epirubicin) are commonly used but require careful monitoring for cardiotoxicity 1.
Liposome-encapsulated doxorubicin (L-ADM) may be considered to mitigate cardiotoxic effects 1.Special Populations
Cardiotoxicity monitoring is particularly critical in elderly patients receiving anthracycline chemotherapy due to increased risk 1.
Specific guidelines for pediatric patients or pregnant women with soft tissue sarcomas are not addressed in the provided abstracts 1.Key Recommendations
Regular echocardiographic monitoring is essential for patients undergoing anthracycline chemotherapy to detect early signs of cardiotoxicity (Evidence: Moderate 1).
Consider liposome-encapsulated doxorubicin to reduce the risk of cardiotoxicity compared to conventional anthracyclines (Evidence: Moderate 1).
Tailor surveillance and treatment intensity based on patient-specific factors, especially age, to manage cardiotoxicity effectively (Evidence: Expert opinion 1).References
1 Mo Z, Deng Y, Bao Y, Liu J, Jiang Y. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience. Cancer medicine 2023. link